J Westra1, P C Limburg, P de Boer, M H van Rijswijk. 1. Department of Rheumatology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, Netherlands. j.westra@med.rug.nl
Abstract
OBJECTIVE: To investigate the effect of the p38 mitogen activated protein kinase (MAPK) inhibitor RWJ 67657 on inflammatory mediator production by rheumatoid synovial fibroblasts (RSF). METHODS: RSF were pretreated with RWJ 67657 and stimulated with TNF alpha and/or IL-1 beta. Protein levels and mRNA expression of MMP-1, MMP-3, TIMP-1, IL-6, and IL-8 were determined, as was mRNA expression of COX-2 and ADAMTS-4. RESULTS: MMP-3 production was significantly inhibited at 1 microM RWJ 67657 and MMP-1 production at 10 microM, while TIMP-1 production was not inhibited. Inhibition of IL-6 and IL-8 protein production was seen at 0.1 microM RWJ 67657. Expression profiles of mRNA were in accordance with protein production. Inhibition of COX-2 mRNA expression occurred at 0.01 microM RWJ 67657. CONCLUSIONS: RWJ 67657 inhibits major proinflammatory mediator production in stimulated RSF at pharmacologically relevant concentrations. These findings could have important relevance for the treatment of rheumatoid arthritis.
OBJECTIVE: To investigate the effect of the p38 mitogen activated protein kinase (MAPK) inhibitor RWJ 67657 on inflammatory mediator production by rheumatoid synovial fibroblasts (RSF). METHODS:RSF were pretreated with RWJ 67657 and stimulated with TNF alpha and/or IL-1 beta. Protein levels and mRNA expression of MMP-1, MMP-3, TIMP-1, IL-6, and IL-8 were determined, as was mRNA expression of COX-2 and ADAMTS-4. RESULTS:MMP-3 production was significantly inhibited at 1 microM RWJ 67657 and MMP-1 production at 10 microM, while TIMP-1 production was not inhibited. Inhibition of IL-6 and IL-8 protein production was seen at 0.1 microM RWJ 67657. Expression profiles of mRNA were in accordance with protein production. Inhibition of COX-2 mRNA expression occurred at 0.01 microM RWJ 67657. CONCLUSIONS: RWJ 67657 inhibits major proinflammatory mediator production in stimulated RSF at pharmacologically relevant concentrations. These findings could have important relevance for the treatment of rheumatoid arthritis.
Authors: Dolly A Parasrampuria; Peter de Boer; Daksha Desai-Krieger; Andrew T Chow; C Richard Jones Journal: J Clin Pharmacol Date: 2003-04 Impact factor: 3.126
Authors: Marcel D Posthumus; Pieter C Limburg; Johanna Westra; Miek A van Leeuwen; Martin H van Rijswijk Journal: J Rheumatol Date: 2002-05 Impact factor: 4.666
Authors: Judith Branger; Bernt van den Blink; Sebastiaan Weijer; Jeffrey Madwed; Carina L Bos; Abhya Gupta; Chan-Loi Yong; Stephen H Polmar; Dariusz P Olszyna; C Erik Hack; Sander J H van Deventer; Maikel P Peppelenbosch; Tom van der Poll Journal: J Immunol Date: 2002-04-15 Impact factor: 5.422
Authors: Elke Kunisch; Muktheshwar Gandesiri; Reneé Fuhrmann; Andreas Roth; Rando Winter; Raimund W Kinne Journal: Ann Rheum Dis Date: 2007-01-12 Impact factor: 19.103
Authors: S J Smith; P S Fenwick; A G Nicholson; F Kirschenbaum; T K Finney-Hayward; L S Higgins; M A Giembycz; P J Barnes; L E Donnelly Journal: Br J Pharmacol Date: 2006-09-04 Impact factor: 8.739
Authors: Barry L Burnette; Shaun Selness; Raj Devraj; Gail Jungbluth; Ravi Kurumbail; Loreen Stillwell; Gary Anderson; Stephen Mnich; Jeffrey Hirsch; Robert Compton; Pamela De Ciechi; Heidi Hope; Michael Hepperle; Robert H Keith; Win Naing; Huey Shieh; Joseph Portanova; Yan Zhang; Jian Zhang; Richard M Leimgruber; Joseph Monahan Journal: Pharmacology Date: 2009-07-04 Impact factor: 2.547